Prosecution Insights
Last updated: November 04, 2026
Application No. 17/264,788

IMPROVING THE EFFICACY AND SAFETY OF ADOPTIVE CELLULAR THERAPIES

Non-Final OA §102§103§112
Filed
Jan 29, 2021
Priority
Jul 30, 2018 — provisional 62/712,102 +1 more
Examiner
WESTON, ALYSSA G
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Angeles Therapeutics, Inc.
OA Round
3 (Non-Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
71 granted / 120 resolved
-0.8% vs TC avg
Strong +51% interview lift
Without
With
+50.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
49 currently pending
Career history
193
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
36.4%
-3.6% vs TC avg
§102
27.9%
-12.1% vs TC avg
§112
24.8%
-15.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 120 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 04 May 2026 has been entered. Status of the Claims Applicant’s submission filed 04 May 2026 has been entered. Claims 1-3, 154-175, and 177-178 are pending. Claims 168-169 and 171-173 have been amended, while claim 176 has been cancelled without prejudice or disclaimer and claim 178 has been newly added. Therefore, prosecution on the merits continues for claims 165-173 and 178 as being drawn to the elected invention and species, with claims 1-3, 154-164, 174-175, and 177 withdrawn for reading on the non-elected inventions and species. All arguments have been fully considered with the status of each prior ground of rejection set forth below. However, it is of note that the amendment to the claims filed on 04 May 2026 does not comply with the requirements of 37 CFR 1.121(c) because claim 170 is listed as “Currently amended” without having any markings indicating amendments. Amendments to the claims filed on or after July 30, 2003 must comply with 37 CFR 1.121(c) which states (emphasis added): (c) Claims. Amendments to a claim must be made by rewriting the entire claim with all changes (e.g., additions and deletions) as indicated in this subsection, except when the claim is being canceled. Each amendment document that includes a change to an existing claim, cancellation of an existing claim or addition of a new claim, must include a complete listing of all claims ever presented, including the text of all pending and withdrawn claims, in the application. The claim listing, including the text of the claims, in the amendment document will serve to replace all prior versions of the claims, in the application. In the claim listing, the status of every claim must be indicated after its claim number by using one of the following identifiers in a parenthetical expression: (Original), (Currently amended), (Canceled), (Withdrawn), (Previously presented), (New), and (Not entered). (1) Claim listing. All of the claims presented in a claim listing shall be presented in ascending numerical order. Consecutive claims having the same status of “canceled” or “not entered” may be aggregated into one statement (e.g., Claims 1–5 (canceled)). The claim listing shall commence on a separate sheet of the amendment document and the sheet(s) that contain the text of any part of the claims shall not contain any other part of the amendment. (2) When claim text with markings is required. All claims being currently amended in an amendment paper shall be presented in the claim listing, indicate a status of “currently amended,” and be submitted with markings to indicate the changes that have been made relative to the immediate prior version of the claims. The text of any added subject matter must be shown by underlining the added text. The text of any deleted matter must be shown by strike-through except that double brackets placed before and after the deleted characters may be used to show deletion of five or fewer consecutive characters. The text of any deleted subject matter must be shown by being placed within double brackets if strike-through cannot be easily perceived. Only claims having the status of “currently amended,” or “withdrawn” if also being amended, shall include markings. If a withdrawn claim is currently amended, its status in the claim listing may be identified as “withdrawn—currently amended.” (3) When claim text in clean version is required. The text of all pending claims not being currently amended shall be presented in the claim listing in clean version, i.e., without any markings in the presentation of text. The presentation of a clean version of any claim having the status of “original,” “withdrawn” or “previously presented” will constitute an assertion that it has not been changed relative to the immediate prior version, except to omit markings that may have been present in the immediate prior version of the claims of the status of “withdrawn” or “previously presented.” Any claim added by amendment must be indicated with the status of “new” and presented in clean version, i.e., without any underlining. (4) When claim text shall not be presented; canceling a claim. (i) No claim text shall be presented for any claim in the claim listing with the status of “canceled” or “not entered.” (ii) Cancellation of a claim shall be effected by an instruction to cancel a particular claim number. Identifying the status of a claim in the claim listing as “canceled” will constitute an instruction to cancel the claim. (5) Reinstatement of previously canceled claim. A claim which was previously canceled may be reinstated only by adding the claim as a “new” claim with a new claim number. As noted above, the amendment under consideration herein fails to comply with 37 CFR 1.121 because instant claim 170 has the status identifier of “Currently amended” without actually having any markings indicating amendments. Thus, the amendment could be considered non-responsive. However, in the interest of compact prosecution the amendment at issue will not be considered non-responsive. The Examiner notes that any future responses failing to comply with 37 CFR 1.121 will be held non-responsive, and will not be considered. Status of Prior Rejections/Response to Arguments RE: Information Disclosure Statement Applicant’s submission of the appropriate size fee set forth under 37 CFR 1.17(v)(2) for the IDS filed 02 September 2025 is acknowledged. It is of note that the total number of references submitted within the application including the IDS filed 13 May 2026 is 113. RE: Objection to the Specification The amendment to the Specification filed 04 May 2025 and supplemental amendment to the Specification filed 26 May 2026 are each acknowledged and entered into the application file. With that, Applicant has failed to remove all prefixes within Paragraph [0260] of the Specification. Therefore, the objection is maintained. The Examiner suggests either deleting the browser-executable code in its entirety, or modifying the recitation to “( RE: Claim Interpretation Applicant has traversed the Examiner’s interpretation of the claims, asserting in Page 21 of the Remarks filed 04 May 2026 that each of the donor characteristics recited in instant claim 171 is not a passive descriptor of donor identity, and is instead a quantitative, functional limitation tied directly to a measurable property of the resulting mobilized immune effector cell. Applicant cites Paragraphs [00179]-[00188] of the instant Specification to support this assertion. In response, the Examiner respectfully submits that Applicant’s arguments fail to disclose how the starting number of cells in the donor’s blood or bone marrow alters the structure of the final mobilized immune effector cell. The Examiner also notes that the cited paragraphs simply recite the limitations as seen in the instant claims, and do not provide any supporting evidence to the structural changes to the final mobilized immune effector cell. Applicant has further traversed the Examiner’s interpretation of the claims, asserting in Page 21 of the Remarks filed 04 May 2026 that each of the downstream operations recited in instant claim 172 impart structural changes to the resulting mobilized immune effector cell. In response, the Examiner respectfully submits that the recited downstream operations in instant claim 172 are “optional” limitations, and are therefore not accorded patentable weight under the broadest reasonable interpretation of the claim. Therefore, the claim interpretations are maintained. RE: Objection to claims 168-169 and 171-173 Applicant’s amendments to each of instant claims 168-169 and 171-173 correct the minor informalities, thus obviating the objections of record. Therefore, the objections are withdrawn. RE: Rejection of claims 169 and 176 under 35 USC 112(b) The cancellation of instant claim 176 renders the rejection moot for that claim. For the remaining claim, Applicant’s amendments to instant claim 169 obviate the rejection of record. Therefore, the rejections are withdrawn. RE: Rejection of claim 176 under 35 USC 101 The cancellation of instant claim 176 renders the rejection moot for that claim. Therefore, the rejection is withdrawn. RE: Rejection of claims 165-173 and 176 under 35 USC 103 over Poznansky et al in view of Lundqvist et al The cancellation of claim 176 renders the rejection moot for that claim. For the remaining claims, Applicant’s arguments have been fully considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Therefore, the rejection is withdrawn. It is of note that Applicant’s arguments regarding the unexpected results in Pages 48-64 of the Remarks filed 04 May 2026 will necessarily be exhibited by the mobilized immune effector cells of King et al (US 2018/0228871 A1, of record on IDS filed 23 July 2024), as they have the same structure as the mobilized immune effector cells of at least independent claim 165. See MPEP § 716.02 and 2112.01, and the 35 USC 102 rejection below. It is further of note that the closest prior art for comparison of the unexpected results is King et al. New/Maintained Grounds of Rejection Specification The substitute Specifications filed 04 May 2026 and 26 May 2026 are acknowledged and entered into the application file. However, the disclosure remains objected to because it contains an embedded hyperlink and/or other form of browser-executable code in Paragraph [0260] of the instant Specification. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. It is of note that the lengthy Specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which Applicant may become aware in the Specification. Claim Interpretation Under the broadest reasonable interpretation of each claim, all of the “optional” limitations are not required. Instant claims 170-172 are directed to products which utilize product-by-process language. The limitations of the process of production are considered only in so far as the process of production imparts distinct structural or chemical characteristics or properties to the claimed product. Therefore, if the product, as claimed, is the same or obvious over a product of the prior art (i.e. is not structurally or chemically distinct), the claim is considered unpatentable over the prior art, even though the prior art product is made by a different process. See MPEP § 2113. Claims 170-171 further define the donor from which the immune effector cells are isolated. When defining the source of cells, the source of the cells is only considered in as far as the source defines the cell as having distinct biochemical or morphological characteristics. In the instant case, the source – or donor – of the immune effector cells does not impart a distinction to the cells, but rather their physical and structural characteristics dictates their classification as a particular cell type. Claim 172 further defines the method in which the blood and/or bone marrow is obtained from the donor. In the instant case, there is no evidence that the isolation method imparts any particular structure or significance to the claimed immune effector cells. Therefore, the claims will be interpreted as if the isolation of cells from the blood and/or bone marrow of any donor, wherein the donor has any characteristic and by using any isolation technique, fulfills the limitations detailed in the instant claims. Claim Objections Claims 167-168 are objected to because of the following informalities: Regarding claim 167: The instant claim is objected to for failing to recite “and” following “a native macrophage receptor” in Line 5. Appropriate correction is required. Regarding claim 168: The instant claim is objected to for reciting “the T cell is selected from” instead of “the T cell is selected from the group consisting of”. See MPEP § 2117. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 168-169 and 172 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 168: The instant claim further defines the T cell as being “selected from alpha/beta T cell, gamma/delta T cell, CD8+ T cell, CD4+ T cell, naïve T cell, Pgp+ T cell, T-regulatory cells, Th-17 cells, stem T cell, T stem memory cell, tissue-resident T cell, tumor infiltrating T cell, natural killer T (NKT) cell or a combination thereof” (emphasis added). Claim language defined by a Markush grouping requires selection from a closed group "consisting of" the alternative members. See MPEP § 2117(I): Id. at 1280, 67 USPQ2d at 1196. The recitation of “or” indicates that the Markush group is open, thus rendering the metes and bounds of the claim indefinite. Appropriate correction is required. Regarding claim 169: The instant claim is rejected once again for the use of parentheticals “Lewis (Y) antigen” in Line 13, “mammary gland differentiation antigen (NY-BR-1)” in Lines 28-29, “lymphocyte antigen 6 complex, locus K9 (LY6K)” in Line 31, “ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML)” in Line 34, “angiopoietin-binding cell surface receptor 2 (Tie 2)” in Lines 35-36, “ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene)” in Line 41, “CSF2RA (GM-CSFR-alpha)” in Line 62 – wherein these limitations were previously rejected in the Office action filed 28 February 2025. While parentheticals can be used as abbreviations, the use of parentheticals adjacent to terms which recite alternate names or isoforms renders the claim indefinite because it is not clear whether the items within the parentheticals are required or optional. Applicant should review the claim and remove any parentheticals that are not expressly utilized as an abbreviation. Appropriate correction is required. Regarding claim 172: The instant claim recites the limitation, “freezing (cryopreservation) of the expanded immune effector cell or population thereof” in option m). The scope of the claim is indefinite, as it is unclear if the parenthetical language is required by the claim, or is instead optional. The Examiner would like to note that there are inherent discrepancies between simply freezing the cells and cryopreserving the cells, especially in regard to the method steps required. Therefore, the metes and bounds of the claim cannot be determined, thus rendering the claim indefinite. Appropriate correction is required. It is of note that this limitation was previously rejected in the Office action filed 28 February 2025, and corrected in the claim listing filed 28 August 2025 to recite “cryopreservation of the expanded immune effector cell or population thereof”. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 165-173 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by King et al (US 2018/0228871 A1, of record on IDS filed 23 July 2024) as evidenced by Sadelain et al (Cancer Discov, 2013). King et al has an effective filing date of 03 August 2015. King et al disclose human peripheral blood T cells that have been isolated from the blood of a human donor who has undergone treatment with the mobilizing agent of Plerixafor, wherein the mobilized T cells are genetically modified to express a polynucleotide encoding a chimeric antigen receptor (Abstract; Paragraphs [0007], [0062], [0067], [0076], [0087], [0107], [0119]). King et al further disclose that the chimeric antigen receptor (CAR) comprises an antigen binding domain specific for prostate specific membrane antigen (PSMA) (Paragraphs [0102], [0107], [0109]-[0110]). It is of note that although King et al do not explicitly disclose that the CAR comprises a transmembrane domain, CARs comprising an antigen binding domain and a costimulatory domain (Paragraph [0107]) will inherently comprise a transmembrane domain. See Page 2 and Figure 1 of Sadelain et al. Accordingly, King et al anticipate the claims as follows: Regarding claims 165-169: King et al as evidenced by Sadelain et al disclose human peripheral blood T cells (claim 168) that have been isolated from the blood of a human donor who has undergone treatment with the mobilizing agent of Plerixafor (claim 166), wherein the mobilized T cells are genetically modified to express a polynucleotide encoding a CAR (claim 167) comprising an antigen binding domain specific for PSMA (claim 169) and a transmembrane domain. This therefore reads on the mobilized immune effector cell of instant claim 165. Regarding claim 170-171: The instant claims are a product-by-process limitation further describing the source – or donor – of the immune effector cells. See Claim Interpretation section above. Accordingly, the source of the cells does not change the cells, per se. Therefore, the instant claims are rejected for the same reason as instant claim 165. However, it is of note that King et al do disclose that the mobilized T cells are isolated from the blood of an autologous donor – which reads on instant claim 170 (Paragraphs [0097], [0119]). Regarding claim 172: The instant claim is a product-by-process limitation further describing the method in which the immune effector cells are isolated. See Claim Interpretation section above. Accordingly, the isolation technique of the cells does not change the cells, per se. Therefore, the instant claim is rejected for the same reason as instant claim 165. However, it is of note that King et al do disclose that the T cells are isolated from the blood of a donor via leukapheresis – which reads on the instant claim (Paragraph [0104]). Regarding claim 173: Following the discussion of claim 166, King et al further disclose that the mobilizing agent is administered via intravenous or subcutaneous routes (Paragraph [0065]). This therefore reads on the mobilized immune effector cell of the instant claim. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 165-173 and 178 are rejected under 35 U.S.C. 103 as being unpatentable over King et al (US 2018/0228871 A1, of record on IDS filed 23 July 2024) as evidenced by Sadelain et al (Cancer Discov, 2013), in view of Peled et al (US 2018/0161366 A1). The discussion of King et al as evidenced by Sadelain et al regarding instant claim 165 can be observed above and is relied upon herein, the content of which is incorporated in its entirety. King et al as evidenced by Sadelain et al anticipate instant claims 165-173. Peled et al is considered prior art under 35 USC 102(a)(1) and 35 USC 102(a)(2), with a publication date of 14 June 2018. Regarding claim 178: As aforementioned in the discussion of claim 165 above, King et al as evidenced by Sadelain et al disclose human peripheral blood T cells that have been isolated from the blood of a human donor who has undergone treatment with the mobilizing agent of Plerixafor, wherein the mobilized T cells are genetically modified to express a polynucleotide encoding a CAR comprising an antigen binding domain specific for PSMA and a transmembrane domain. King et al fail to disclose that the mobilized T cells are cryopreserved prior to being genetically modified to express a polynucleotide encoding a CAR, as required by instant claim 178. Peled et al, however, disclose methods of obtaining mononuclear blood cells (Abstract). As such, Peled et al disclose the isolation of mobilized T cells from a subject treated with the CXCR4 antagonist of BL-8040, the cryopreservation of the mobilized T cells, and then thawing and engineering the mobilized T cells to express a CAR (Paragraphs [0004], [0178], [0238]-[0239], [0411]-[0417], [0436]-[0439]). Therefore, it would have been prima facie obvious to have modified the mobilized T cells of King et al such that they are cryopreserved prior to being engineered with a polynucleotide encoding a CAR, as detailed in Peled et al. One of ordinary skill in the art before the effective filing date of the invention would have been motivated to have a means to store the mobilized T cells long-term prior to engineering (Peled et al: Paragraph [0238]), and would have had a reasonable expectation of success given that the disclosures of King et al and Peled et al are both concerned with the mobilization of T cells from blood via a CXCR4 antagonist with the subsequent genetic modification of those mobilized T cells, and that the methods of cryopreservation of well-known in the art (Peled et al: Paragraph [0239]). See MPEP § 2143(I)(G). Consequently, King et al as evidenced by Sadelain et al and as modified by Peled et al render obvious a mobilized T cell that has been cryopreserved prior to being engineered to express a CAR. This therefore renders obvious the mobilized immune effector cell of the instant claim. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALYSSA G WESTON whose telephone number is (571)272-0337. The examiner can normally be reached Monday-Thursday 8AM - 4PM (CT); Friday 8AM - 11AM (CT). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher Babic can be reached at (571) 272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALYSSA G WESTON/Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Jan 29, 2021
Application Filed
Jul 05, 2024
Response after Non-Final Action
Feb 28, 2025
Non-Final Rejection mailed — §102, §103, §112
Aug 28, 2025
Response Filed
Nov 03, 2025
Final Rejection mailed — §102, §103, §112
May 04, 2026
Request for Continued Examination
May 05, 2026
Response after Non-Final Action
Sep 16, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767934
VACCINES BASED ON MUTANT CALR AND JAK2 AND THEIR USES
2y 5m to grant Granted Oct 20, 2026
Patent 12757893
METHODS FOR CRYOGENIC STORAGE
7y 1m to grant Granted Oct 13, 2026
Patent 12760087
MODIFIED T CELL, PREPARATION METHOD THEREFOR AND USE THEREOF
5y 0m to grant Granted Oct 13, 2026
Patent 12735677
METHOD FOR PRODUCING ASTROCYTE-LIKE CELLS
3y 6m to grant Granted Sep 15, 2026
Patent 12723062
METHODS OF TREATING MITOCHONDRIAL DISORDERS
2y 3m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+50.7%)
3y 6m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 120 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month